Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Featured Articles
(AbbVie) Oct 17, 2018 - If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment. The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which showed longer progression-free survival for IMBRUVICA plus...
Read Article
(STAT Plus) Oct 9, 2018 - A promising but controversial new approach to treating blood cancer could be in trouble in the earliest innings of human testing after Celgene pulled the plug on a trailblazing clinical trial. On Monday, Celgene terminated a Phase 1 study of CC-90002, which targets a protein that helps cancer cells stay out...
Read Article
Latest Articles
October 18, 2018
October 16, 2018
October 15, 2018
October 12, 2018
October 12, 2018
October 09, 2018
October 09, 2018
October 05, 2018
View More
News Commentary
Editor Image
09 Jul, 2018 | by Winston Wong, PharmD
The math is simple. Under the proposed agreement, we pay for all doses of the...
View Comment
Editor Image
05 Apr, 2018 | by Winston Wong, PharmD
From a payer perspective, the CMS approval for coverage means that...
View Comment
View More
OBR Blog
There are no Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis) blog entries.